The U.S. Food and Drug Administration (FDA) has limited the authorized use of Johnson & Johnson's Janssen COVID-19 vaccine to certain individuals due to risk of thrombotic events. The vaccine may still be used in people over the age of 18 who have experienced a reaction after an mRNA COVID vaccine, people who have concerns over mRNA vaccine use and would otherwise not receive a vaccine, and people with limited access to mRNA vaccines.

The Janssen vaccine was authorized for emergency use on February 27, 2021, but vaccine administration was paused in April of that year to investigate six reported cases of thrombosis with thrombocytopenia syndrome (TSS). The pause was lifted 10 days later following a safety evaluation. There have been a total of 15 cases of TSS reported following administration of the Janssen COVID vaccine, including those original six. After reviewing reported cases, the FDA determined that the risk...

You do not currently have access to this content.